In cardiac surgery, the slow shift to perform coronary bypass graft procedures off-pump has turned anastomotic device technology, a long dormant area of product development, into a hot subject at clinical meetings and attracted the attention of large and small device companies. One start-up, Ventrica, was founded to focus on a new bypass procedure, but shifted its emphasis to an important component of that procedure: an automated coronary anastomotic connector. The company's magnetic technology has given it a head-start on this hardest part of the bypass connector puzzle. Some industry experts and surgeons believe that an easy-to-use, reproducible, automated anastomotic device will boost adoption of off-pump bypass surgery, which has lagged far below initial expectations and will also be essential to the future of robotic surgery. Ventrica's challenge is to attract new groups of surgeons to this approach rather than simply preach to already-converted early adopters.
by Stephen Levin
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.
“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.
Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.
“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.
The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.
